NCT00214864 - A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

January 31, 2006

Conditions

Metastatic Breast Cancer

Interventions

DRUG

docetaxel, capecitabine

cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1\&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8

Trial Locations (1)

33324

Cancer Research Network, Inc., Plantation